Patents by Inventor Ruichao Shen

Ruichao Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10968249
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: April 6, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
  • ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20200361920
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Application
    Filed: May 11, 2020
    Publication date: November 19, 2020
    Inventors: Guoqiang Wang, Jun Ma, Bin Wang, Ruichao Shen, Xuechao Xing, Yong He, Yat Sun Or
  • Isoxazole derivatives as FXR agonists and methods of use thereof
    Patent number: 10829486
    Abstract: The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: November 10, 2020
    Assignee: Enanta Pharmacueticals, Inc.
    Inventors: Ruichao Shen, Jun Ma, Guoqiang Wang, Xuechao Xing, Yat Sun Or
  • BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20200347092
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: May 19, 2020
    Publication date: November 5, 2020
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200331890
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: May 5, 2020
    Publication date: October 22, 2020
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10696713
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: June 30, 2020
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
  • Isoxazole analogs as FXR agonists and methods of use thereof
    Patent number: 10689391
    Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: June 23, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang, Xuechao Xing, Ruichao Shen, Bin Wang
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10683289
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: June 16, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yat Sun Or
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10683279
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 16, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200157095
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: November 19, 2019
    Publication date: May 21, 2020
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Bin Wang, Yat Sun Or
  • BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20200109164
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: October 4, 2019
    Publication date: April 9, 2020
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
    Patent number: 10597391
    Abstract: The present invention provides compounds of Formula I, Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 24, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jing He, Guoqiang Wang, Ruichao Shen, Xuechao Xing, Bin Wang, Jun Ma, Yat Sun Or
  • Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10597382
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: March 24, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Jing He, Bin Wang, Ruichao Shen, Brett Granger, Yat Sun Or
  • ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20200079764
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: September 13, 2019
    Publication date: March 12, 2020
    Inventors: Jun Ma, Guoqiang Wang, Bin Wang, Xuechao Xing, Ruichao Shen, Jing He, Yat Sun Or
  • Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10519191
    Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: December 31, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Ruichao Shen, Peng Dai, Jiang Long, Xuechao Xing, Guoqiang Wang
  • Bile acid derivatives as FXR agonists and methods of use thereof
    Patent number: 10472386
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 12, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20190337935
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).
    Type: Application
    Filed: May 1, 2019
    Publication date: November 7, 2019
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yat Sun Or
  • TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20190337923
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: May 1, 2019
    Publication date: November 7, 2019
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun MA, Bin Wang, Yat Sun Or
  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10457703
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: October 29, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10450301
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 22, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Bin Wang, Yat Sun Or